The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Current Best Clinical Practices—Management of Neovascular AMD
Abstract
The hallmark feature of the wet or neovascular form of age-related macular degeneration is the presence of choroidal (or retinal) neovascularization (CNV). If left untreated, CNV may result in significant central vision loss due to complications including exudation, leakage, and ultimately subretinal fibrosis causing remarkable photoreceptor loss. Although the mechanism of development is not fully understood, the process of neovascularization is driven by the upregulation of angiogenic cytokines, principally vascular endothelial growth factor (VEGF). Inhibition of VEGF with intravitreal anti-VEGF therapy has become the standard of care for macular CNV, helping to prevent legal blindness in millions of affected patients worldwide.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Repeated intravitreal (IVT) injections of anti-VEGF therapies effectively slow vision loss in the majority of treatment-compliant patients with wet AMD. 7 – 13”
From Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies (2024) · cites this paper as [7]
In the citing paper
“However, the requirement for lifelong injections imposes a substantial burden on patients and caregivers, and many patients fail to maintain initial therapeutic benefits owing to noncompliance with the burdensome treatment regimen. 3 , 7 , 8 , 10 , 13 – 20”
From Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies (2024) · cites this paper as [7]
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Self-citationRanibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
Self-citationRanibizumab and bevacizumab for neovascular age-related macular degeneration
(2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102673 · Cited by 2,669
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration
Heier, J. S., Brown, D. M., Chong, V., Korobelnik, J.-F., Kaiser, P. K., Nguyen, Q. D., Kirchhof, B., Ho, A., Ogura, Y., Yancopoulos, G. D., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.09.006 · Cited by 2,485
Self-citationPegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
Martin, D. F., Maguire, M. G., Fine, S. L., Ying, G.-S., Jaffe, G. J., Grunwald, J. E., Toth, C., Redford, M., & Ferris, F. L. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.03.053 · Cited by 1,715
Intravitreal Aflibercept Injection for Neovascular Age-related Macular Degeneration
Schmidt-Erfurth, U., Kaiser, P. K., Korobelnik, J.-F., Brown, D. M., Chong, V., Nguyen, Q. D., Ho, A. C., Ogura, Y., Simader, C., Jaffe, G. J., et al. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.08.011 · Cited by 822 · cited 1×
“In year 2 of the aflibercept trials, patients were treated at least every 12 weeks with additional treatments given “as needed” based on q4W study visits.(5) Occasionally, off-label treatment with a drug that is FDA approved for 1 disease is found to be efficacious for a nonFDA-approved indication.”
MethodSelf-citationBusbee, B. G., Ho, A. C., Brown, D. M., Heier, J. S., Suñer, I. J., Li, Z., Rubio, R. G., & Lai, P. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2012.10.014 · Cited by 500
Self-citationBerg, K., Pedersen, T. R., Sandvik, L., & Bragadóttir, R. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2014.07.041 · Cited by 392
(2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.11.031 · Cited by 283
Research works printed but not linked: 3
- Solomon SD, 2014, Cochrane Database Syst Rev, 29, CD005139
- Stewart MW, 2012, Retina, 32, 434
- Stone TW, 2015, ASRS 2015 Preferences and Trends Membership Survey
Cited by
Age-Related Macular Degeneration
Thomas, C. J., Mirza, R. G., & Gill, M. K. (2021) · Medical Clinics of North America · doi:10.1016/j.mcna.2021.01.003 · Cited by 399
“For wet AMD, anti-VEGF agents have proven to be beneficial in targeting CNV lesions and preserving vision.(34) VEGF is present throughout the body and required for normal angiogenesis.”
BackgroundAdvances in Biodegradable Nano-Sized Polymer-Based Ocular Drug Delivery
Lynch, C. R., Kondiah, P. P. D., Choonara, Y. E., du Toit, L. C., Ally, N., & Pillay, V. (2019) · Polymers · doi:10.3390/polym11081371 · Cited by 98
Hanson, R. L. W., Airody, A., Sivaprasad, S., & Gale, R. P. (2022) · Eye · doi:10.1038/s41433-022-02360-4 · Cited by 75
“OCT-guided treatment following an as required (pro re nata or ‘prn’) regimen was shown to be as beneficial as a fixed monthly regimen in the HARBOR study [15], However in real-world studies including AURA and LUMINOUS, prn outcomes fall short of this standard [16, 17] and proactive treatment with a variable treatment…”
ResultInfluentialMelinščak, M., Radmilović, M., Vatavuk, Z., & Lončarić, S. (2021) · Automatika · doi:10.1080/00051144.2021.1973298 · Cited by 70
Tamashiro, T., Tanaka, K., Itagaki, K., Nakayama, M., Maruko, I., Wakugawa, S., Terao, N., Onoe, H., Wakatsuki, Y., Ogasawara, M., et al. (2022) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-021-05517-1 · Cited by 35
Metadata
- Authors
- Brown, D., Heier, J. S., Boyer, D. S., Freund, K. B., Kaiser, P., Kim, J. E., & Sarraf, D.
- Affiliations
- Houston Methodist (US)
- Ophthalmic Consultants of Boston (US)
- Retina Vitreous Associates Medical Group (US)
- Vitreous Retina Macula Consultants of New York (US)
- Cleveland Clinic (US)
- Medical College of Wisconsin (US)
- University of California, Los Angeles (US)
- Corresponding author
- Heier, Jeffrey S.
- ORCID
- Venue
- Journal of VitreoRetinal Diseases
- Publisher
- SAGE Publications
- Published
- 2017-08-16
- Volume
- 1
- Issue
- 5
- Pages
- 294-297
- ISSN
- 2474-1264 (ISSN-L)
- 2474-1272
- OpenAlex
- W2750115411
- Cited by
- 23
- References
- 24
- Citations by year
- 2026: 3 · 2025: 1 · 2024: 3 · 2023: 3 · 2022: 5 · 2021: 4 · 2020: 3 · 2019: 1
- FWCI
- 1.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of VitreoRetinal Diseases (publishedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Keywords
- neovascular age-related macular degeneration, choroidal neovascularization, anti-VEGF therapy, intravitreal injection, vascular endothelial growth factor, angiogenesis, subretinal fibrosis, photoreceptor loss, blindness prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Current Best Clinical Practices—Management of Neovascular AMD. https://app.cochat.ai/papers/10.1177/2474126417725946
- The paper
- Brown, D., Heier, J. S., Boyer, D. S., Freund, K. B., Kaiser, P., Kim, J. E., & Sarraf, D. (2017). Current Best Clinical Practices—Management of Neovascular AMD. Journal of VitreoRetinal Diseases. https://doi.org/10.1177/2474126417725946
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.